ALS Alert mastheadALS Alert mastheadFall 2002 - Science. Scope. Speed

ALS Center Web Site
Research
People and Events

In This Issue:

New Drug Screen: Uncle Sam’s Grand Present
Late this summer, 12 potential new ALS drugs—a jaw-dropping number—made their way into the Center’s first stages of animal testing thanks to an unusual project linking Center scientists and researchers across the country.

Center Scientist Eyes Key Step in Cells’ ‘Death March’
A current hot spot in als research centers on something long ignored as a source of trouble in the disease: the mitochondria. The plentiful, often jellybean-shaped cell bodies are dubbed the cell’s powerhouses because they generate most of its energy.

Accentuate the Positive
Some Center scientists, eying a cure, seek the cause of ALS. Others study how it damages cells. But a third group’s work may lessen immediate misery: They’re learning the basics of damage control and repair.

The Aggregate Dilemma: Too Obvious to Ignore
For years, scientists have noted obvious clumps of protein in motor neurons of patients with both sporadic and inherited forms of ALS—those who have a mutated gene for the SOD1 enzyme.

A Wedding to Remember
“I’ve come to realize what good friends are. People you knew but didn’t know have become friends. There’s a depth to it I hadn’t experienced before.”

Available Issues:

Winter 2001/2002
Fall 2002
Spring 2003
Fall 2003
Spring 2004
Fall 2004
Winter 2005
Spring/Summer 2005
Fall 2005
Winter 2006

About ALS Alert


From the Clinic

photo - Lora Clawson, M.S.N., C.R.N.P., manages Johns Hopkins’ ALS clinic. She also oversees its clinical trials.  
Lora Clawson, M.S.N., C.R.N.P.
   

Lora Clawson, M.S.N., C.R.N.P., manages Johns Hopkins’ ALS clinic. She also oversees its clinical trials.

It’s been a half-year since my ALS diagnosis and, while I generally know the disease’s course, it’d be helpful to learn more exactly what comes when. Nobody discusses that with me.
Because ALS is unpredictable, every patient progresses differently. And though the disease advances in a set way within cells, what happens to the whole body varies from person to person, both in the order and timing of what body part’s affected. In our clinic, for example, we have the sense that weakness starting, say, in the right leg, next moves to an adjacent limb—the right arm or left leg. But we can’t predict which.

At times, some patients report that the disease seems to speed up. But studies show that the rate of motor neuron death within a muscle remains constant.

Mostly, times that patients tell us their ALS has quickened follow a major lifestyle change—in feeding themselves, for example, or in needing breathing help. We believe heightened awareness of the disease makes it seem to progress faster.

True, some people are “rapid progressors” throughout, while others are slow and stay that way. After three or four consecutive monthly visits, we get a feel for a patient’s rate. Then we help plan an approach as the disease progresses.

If ALS undeniably progresses, why should I keep up my clinic visits?
When patients feel well, they often don’t want to see other patients. Being constantly reminded of ALS is stressful. Others find it difficult to travel, or family members can’t get off work. Many valid reasons exist for not coming to a comprehensive clinic.

But there’s a down side to letting visits lapse. Regular appointments let us help patients deal with where they are in the course of the disease—they help optimize the good and handle the bad. Visits let us stay ahead of problems and avoid surprises. They permit interventions that may stave off the next stage a little longer. If a patient is losing weight, for example, we can advise specific changes in preparing meals or in calorie content that can delay the need for a gastrostomy tube.

Also important: Scheduled visits tell us how patients and their families are coping. Patients who have difficulty, say, in changing the way they brush their teeth, who resist alternate ways to accomplish tasks, may shorten survival. We know mourning losses gets in the way. But research on ALS and other illnesses such as cardiac disease shows that flexibility and a positive attitude make a difference.

Next > A Friend Indeed
With ALS Support, It’s Never ‘Too Many Cooks’


Sign up for ALS news, the print version of the newsletter and more:
   
Special Features:

Vantage point
What, exactly, does ALS do to motor neuron cells? In this issue, several of our articles feature the Center’s efforts to answer that crucial question.

On Center: New Name and ‘Wings’ Give Center Zing
Put 1,700 Wall Street investment bankers, ALS patients and supporters in one of the New York Marriott Marquis’ grand ballrooms, add hors d’oeuvres and some Hollywood “biggies” and you have this year’s Wings Over Wall Street.

Insider’s View
Nicholas Maragakis, M.D., is a Hopkins neurologist/researcher who specializes in neuromuscular diseases. In this column he answers questions.

From the Clinic
Lora Clawson, M.S.N., C.R.N.P., manages Johns Hopkins’ ALS clinic. She also oversees its clinical trials. In this column she answers typical patients’ questions.

A Friend Indeed
With ALS Support, It’s Never ‘Too Many Cooks’

Make a Donation



© Copyright 2002 | All Rights Reserved | Robert Packard Center for ALS Research at Johns Hopkins
600 N. Wolfe Street, Meyer 6-109, Baltimore, Maryland 21287-5953 USA
Site Index Frequently Asked Questions Contact Us Hopkins Medicine